BR9807234B1 - Composição farmacêutica compreendendo um composto tricílico e uma combinação de miristrato de isopropila e sebacato de dietila, com estabilidade e absorbilidade aumentadas e um pontencial de irritação reduzido - Google Patents

Composição farmacêutica compreendendo um composto tricílico e uma combinação de miristrato de isopropila e sebacato de dietila, com estabilidade e absorbilidade aumentadas e um pontencial de irritação reduzido

Info

Publication number
BR9807234B1
BR9807234B1 BRPI9807234-0B1A BR9807234A BR9807234B1 BR 9807234 B1 BR9807234 B1 BR 9807234B1 BR 9807234 A BR9807234 A BR 9807234A BR 9807234 B1 BR9807234 B1 BR 9807234B1
Authority
BR
Brazil
Prior art keywords
tricyl
isopropil
absorbility
irritation
compound
Prior art date
Application number
BRPI9807234-0B1A
Other languages
English (en)
Other versions
BR9807234A (pt
Inventor
Masayuki Yamanaka
Fumio Shimojo
Satoshi Ueda
Rinta Ibuki
Norio Ohnishi
Toshihiko Toyoda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR9807234A publication Critical patent/BR9807234A/pt
Publication of BR9807234B1 publication Critical patent/BR9807234B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
BRPI9807234-0B1A 1997-02-20 1998-02-18 Composição farmacêutica compreendendo um composto tricílico e uma combinação de miristrato de isopropila e sebacato de dietila, com estabilidade e absorbilidade aumentadas e um pontencial de irritação reduzido BR9807234B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP3617297 1997-02-20
JP25635797 1997-09-22
PCT/JP1998/000665 WO1998036747A1 (en) 1997-02-20 1998-02-18 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
BR9807234A BR9807234A (pt) 2000-04-25
BR9807234B1 true BR9807234B1 (pt) 2013-11-05

Family

ID=26375217

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9807234-0B1A BR9807234B1 (pt) 1997-02-20 1998-02-18 Composição farmacêutica compreendendo um composto tricílico e uma combinação de miristrato de isopropila e sebacato de dietila, com estabilidade e absorbilidade aumentadas e um pontencial de irritação reduzido

Country Status (21)

Country Link
US (1) US6387918B1 (pt)
EP (1) EP0977565B1 (pt)
JP (1) JP3396888B2 (pt)
KR (1) KR100490357B1 (pt)
CN (1) CN1178656C (pt)
AR (1) AR011846A1 (pt)
AT (1) ATE237325T1 (pt)
AU (1) AU727337B2 (pt)
BR (1) BR9807234B1 (pt)
CA (1) CA2282345C (pt)
DE (1) DE69813542T2 (pt)
DK (1) DK0977565T3 (pt)
EA (1) EA003580B1 (pt)
ES (1) ES2193515T3 (pt)
HK (1) HK1027957A1 (pt)
HU (1) HU226163B1 (pt)
IL (1) IL131298A (pt)
NO (1) NO325103B1 (pt)
PT (1) PT977565E (pt)
TW (1) TW450810B (pt)
WO (1) WO1998036747A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100406823B1 (ko) * 1998-04-27 2003-11-21 후지사와 야꾸힝 고교 가부시키가이샤 의약 조성물
GB9817064D0 (en) * 1998-08-05 1998-10-07 Fujisawa Pharmaceutical Co New use
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
AUPR529701A0 (en) * 2001-05-28 2001-06-21 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition
JP4447914B2 (ja) 2001-11-29 2010-04-07 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節物質を含む医薬品
ES2428354T3 (es) * 2002-09-18 2013-11-07 Trustees Of The University Of Pennsylvania Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
SI1663217T1 (sl) 2003-08-29 2010-10-29 Lifecycle Pharma As Trdne disperzije, ki vsebujejo takrolimus
BRPI0413927B8 (pt) 2003-08-29 2021-05-25 Lifecycle Pharma As composição farmacêutica compreendendo tacrolimus, forma de dosagem, uso da composição, e, método para a preparação da composição
WO2005027906A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
KR20070104931A (ko) * 2005-02-09 2007-10-29 마커사이트, 인코포레이티드 안구 치료용 제제
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
US7672006B2 (en) * 2006-02-22 2010-03-02 Xerox Corporation Multi-marking engine printing platform
DK2001466T3 (en) * 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
JP2009533440A (ja) * 2006-04-10 2009-09-17 メルク エンド カムパニー インコーポレーテッド Ｃｇｒｐ拮抗薬塩
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
HUE033011T2 (hu) 2007-05-30 2017-11-28 Veloxis Pharmaceuticals As Takrolimuszt tartalmazó napi egyszeri orális dózisforma
US8575189B2 (en) * 2008-10-08 2013-11-05 Takata Seiyaku Co., Ltd. Tacrolimus preparation for external applications
EA027869B1 (ru) * 2010-02-17 2017-09-29 Велоксис Фармасьютикалз А/С Стабилизированная композиция такролимуса
JP5674786B2 (ja) * 2010-07-23 2015-02-25 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
WO2012011192A1 (ja) 2010-07-23 2012-01-26 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
WO2013084995A1 (ja) * 2011-12-07 2013-06-13 久光製薬株式会社 貼付剤
JP6084579B2 (ja) * 2012-01-25 2017-02-22 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
MX2018001989A (es) 2015-08-19 2018-06-19 Vivus Inc Formulaciones farmaceuticas.
EP3641725A1 (en) 2017-06-23 2020-04-29 The Procter and Gamble Company Composition and method for improving the appearance of skin
WO2019233722A1 (en) 2018-06-08 2019-12-12 Almirall, S.A. Pharmaceutical composition comprising tacrolimus
EP3817717A1 (en) 2018-07-03 2021-05-12 The Procter & Gamble Company Method of treating a skin condition
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
JP2023528616A (ja) 2020-06-01 2023-07-05 ザ プロクター アンド ギャンブル カンパニー ビタミンｂ３化合物の皮膚への浸透を改善する方法
CN117177749A (zh) 2021-03-03 2023-12-05 萨那生物科技公司 与心肌细胞疗法一起使用的免疫抑制疗法以及相关的方法和组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0406791T3 (da) * 1989-07-05 1995-03-27 Fujisawa Pharmaceutical Co Vandigt flydende præparat til ekstern anvendelse
ATE150304T1 (de) * 1990-09-04 1997-04-15 Fujisawa Pharmaceutical Co Tricyclische verbindungen enthaltende salben
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
JPH06183970A (ja) 1992-12-16 1994-07-05 Fujisawa Pharmaceut Co Ltd 医薬用組成物
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
EP0786986B1 (en) 1994-10-26 2002-03-20 Novartis AG Use of an unsaturated fatty alcohol

Also Published As

Publication number Publication date
AU6228998A (en) 1998-09-09
NO325103B1 (no) 2008-02-04
US20020032212A1 (en) 2002-03-14
CN1252721A (zh) 2000-05-10
JP2000513739A (ja) 2000-10-17
HUP0000979A3 (en) 2002-10-28
EP0977565B1 (en) 2003-04-16
KR20000070824A (ko) 2000-11-25
NO994003D0 (no) 1999-08-19
CA2282345A1 (en) 1998-08-27
KR100490357B1 (ko) 2005-05-17
WO1998036747A1 (en) 1998-08-27
JP3396888B2 (ja) 2003-04-14
ATE237325T1 (de) 2003-05-15
CN1178656C (zh) 2004-12-08
DE69813542D1 (de) 2003-05-22
HU226163B1 (en) 2008-05-28
NO994003L (no) 1999-10-19
DE69813542T2 (de) 2003-11-20
HK1027957A1 (en) 2001-02-02
EP0977565A1 (en) 2000-02-09
CA2282345C (en) 2008-10-21
EA199900749A1 (ru) 2000-04-24
DK0977565T3 (da) 2003-08-04
AU727337B2 (en) 2000-12-07
IL131298A0 (en) 2001-01-28
ES2193515T3 (es) 2003-11-01
US6387918B1 (en) 2002-05-14
AR011846A1 (es) 2000-09-13
BR9807234A (pt) 2000-04-25
TW450810B (en) 2001-08-21
PT977565E (pt) 2004-01-30
HUP0000979A1 (hu) 2000-10-28
IL131298A (en) 2004-06-20
EA003580B1 (ru) 2003-06-26

Similar Documents

Publication Publication Date Title
BR9807234B1 (pt) Composição farmacêutica compreendendo um composto tricílico e uma combinação de miristrato de isopropila e sebacato de dietila, com estabilidade e absorbilidade aumentadas e um pontencial de irritação reduzido
KR970006279A (ko) 약제학적 활성 성분으로서의 6-디메틸아미노메틸-1-페닐-사이클로헥산 화합물
FI973828A (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
ID18663A (id) Komposisi farmasi berlapis enterik
DE69634053D1 (de) Oral anzuwendende Arzneizusammensetzung enthaltend 2-Methyl-thienobenzodiazepin
NO962606D0 (no) Farmasöytisk sammensetning
FI955144A (fi) Päällystetyt farmaseuttiset koostumukset
HUP9601566A3 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
EE9700241A (et) Farmatseutiline kompositsioon transdermaalseks manustamiseks
BR9609738A (pt) Composições para aplicação de droga para estabilidade melhorada de esteróides
FI970825A (fi) Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyötyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria
PT1066027E (pt) Composicao farmaceutica de topiramato
DK1035833T3 (da) Sammensætning til nasal indgivelse
FI972292A0 (fi) Administrering av diabetes
ID22973A (id) Komposisi farmasi dari pemberian oral dari turunan n-piperidino-3-pirazolkarboksamida, garam-garam dan solvatnya
IS4706A (is) Lyfjasamsetningar
PT907364E (pt) Composicao farmaceutica de libertacao sustida
PT946185E (pt) Composicao farmaceutica compreendendo um composto que possui actividade anti-xa e um composto antagonista da agregacao plaquetaria
EE200000226A (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
FI973229A (fi) Uusi farmaseuttinen koostumus
LV11727A (lv) Farmaceitiska kompozicija
ID29294A (id) Komposisi farmasi
MA26531A1 (fr) Composition pharmaceutique
ID25857A (id) Komposisi farmasi
FI973280A (fi) Farmaseuttinen koostumus

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP)

Free format text: TRANSFERIDO POR FUSAO DE: FUJISAWA PHARMACEUTICAL CO., LTD.

B25D Requested change of name of applicant approved

Owner name: ASTELLAS PHARMA INC. (JP)

Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM ARTIGO 37, E COM BASE NOS ARTIGOS 8O, 13 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/11/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)